{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:19:21Z","timestamp":1784614761548,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"DAE-ACTREC","award":["4598"],"award-info":[{"award-number":["4598"]}]},{"name":"Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) - Khargar"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-025-01966-1","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:22:01Z","timestamp":1759918921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The synergistic action of HDAC inhibitor with cisplatin impedes survival and proliferation of drug-tolerant persister in gastric and liver cancer cells"],"prefix":"10.1186","volume":"17","author":[{"given":"Anjali","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhiram","family":"Natu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flevia","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemalatha","family":"Muthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Khade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane T.","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Ashktorab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"1966_CR1","unstructured":"International Agency for Research on Cancer. Gastrointestinal cancers. Global Cancer Observatory; Available from: https:\/\/gco.iarc.fr\/stories\/gastro-intestinal\/en."},{"issue":"2","key":"1966_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf020","volume":"30","author":"T Jang","year":"2025","unstructured":"Jang T, Kim GP, George TJ. Select updates from ASCO and ESMO 2024 for gastrointestinal cancer care. Oncologist. 2025;30(2):oyaf020.","journal-title":"Oncologist"},{"issue":"1","key":"1966_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","volume":"159","author":"M Arnold","year":"2020","unstructured":"Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335-49.e15.","journal-title":"Gastroenterology"},{"issue":"1","key":"1966_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2023.0125","volume":"30","author":"K Sankar","year":"2024","unstructured":"Sankar K, Gong J, Osipov A, et al. Recent advances in the management of hepatocellular carcinoma. Clin Mol Hepatol. 2024;30(1):1\u201315.","journal-title":"Clin Mol Hepatol"},{"issue":"15","key":"1966_CR5","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.3390\/ijms21155500","volume":"21","author":"M Canale","year":"2020","unstructured":"Canale M, Casadei-Gardini A, Ulivi P, Arechederra M, Berasain C, Lollini PL, et al. Epigenetic mechanisms in gastric cancer: potential new therapeutic opportunities. Int J Mol Sci. 2020;21(15):5500.","journal-title":"Int J Mol Sci"},{"issue":"7517","key":"1966_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"key":"1966_CR7","doi-asserted-by":"crossref","unstructured":"Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. Vol. 16, Journal of Hematology and Oncology. BioMed Central Ltd; 2023.","DOI":"10.1186\/s13045-023-01451-3"},{"key":"1966_CR8","doi-asserted-by":"crossref","unstructured":"Burz C, Pop V, Silaghi C, Lupan I, Samasca G. Prognosis and Treatment of Gastric Cancer: A 2024 Update.\u00a0Cancers (Basel). 2024;16(9):1708. Published 2024 Apr 27","DOI":"10.3390\/cancers16091708"},{"issue":"1","key":"1966_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.5230\/jgc.2025.25.e10","volume":"25","author":"SS Eom","year":"2025","unstructured":"Eom SS, Ryu KW, Han HS, Kong SH. A comprehensive and comparative review of global gastric cancer treatment guidelines: 2024 update. J Gastric Cancer. 2025;25(1):153\u201376.","journal-title":"J Gastric Cancer"},{"key":"1966_CR10","doi-asserted-by":"crossref","unstructured":"Abhiram Natu 1 AS 1, SG 1. Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. World J Hepatol. 2021 Nov 27;11(13(11):):1568\u201383.","DOI":"10.4254\/wjh.v13.i11.1568"},{"issue":"1","key":"1966_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2023.0125","volume":"30","author":"K Sankar","year":"2024","unstructured":"Sankar K, Gong J, Osipov A, et al. Recent advances in the management of hepatocellular carcinoma. Clin Mol Hepatol. 2024;30(1):1\u201315.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"1966_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/aid2.13296","volume":"10","author":"T Cheng","year":"2023","unstructured":"Cheng T, Cheng Y, Wu C, Tzeng I, Wang C. Predictors of recurrence in early hepatocellular carcinoma patients treated with surgical resection. Adv Digest Med. 2023;10(1):21\u20137.","journal-title":"Adv Digest Med"},{"key":"1966_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.17998\/jlc.2025.02.03","volume":"25","author":"H Shin","year":"2025","unstructured":"Shin H, Yu SJ, Korean Liver Cancer Association. A concise review of updated global guidelines for the management of hepatocellular carcinoma: 2017\u20132024. J Liver Cancer. 2025;25:19\u201330.","journal-title":"J Liver Cancer"},{"issue":"12","key":"1966_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.821212","volume":"28","author":"X Li","year":"2022","unstructured":"Li X, Yang DH, Ranganathan P. Editorial: chemo-resistance in gastrointestinal cancers. Front Oncol. 2022;28(12):821212.","journal-title":"Front Oncol"},{"key":"1966_CR15","doi-asserted-by":"crossref","unstructured":"Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, et al. Galluzzi, L., Vitale, I., Michels, J.\u00a0et al.\u00a0Systems biology of cisplatin resistance: past, present and future.\u00a0Cell Death Dis\u00a05, e1257 (2014)..","DOI":"10.1038\/cddis.2013.428"},{"key":"1966_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12032-023-02237-w","volume":"41","author":"R Fu","year":"2024","unstructured":"Fu R, Zhao B, Chen M, et al. Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy. Med Oncol.  2024;41:9.","journal-title":"Med Oncol"},{"issue":"11","key":"1966_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","volume":"20","author":"Y Pu","year":"2023","unstructured":"Pu Y, Li L, Peng H, Liu L, Heymann D, Robert C, et al. Drug-tolerant persister cells in cancer: the cutting edges and future directions. Nat Rev Clin Oncol. 2023;20(11):799\u2013813.","journal-title":"Nat Rev Clin Oncol"},{"key":"1966_CR18","doi-asserted-by":"crossref","unstructured":"Vallette FM, Olivier C, L\u00e9zot F, Oliver L, Cochonneau D, Lalier L, et al. Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer. Vol. 162, Biochemical Pharmacology. Elsevier Inc.; 2019. p. 169\u201376.","DOI":"10.1016\/j.bcp.2018.11.004"},{"key":"1966_CR19","doi-asserted-by":"crossref","unstructured":"Chen M, Mainardi S, Lieftink C, Velds A, de Rink I, Yang C, et al. Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse. Cell Rep Med. 2024 Mar 19;5(3).","DOI":"10.1016\/j.xcrm.2024.101471"},{"key":"1966_CR20","doi-asserted-by":"crossref","unstructured":"Chen YC, Gowda K, Amin S, Schell TD, Sharma AK, Robertson GP. Pharmacological agents targeting drug-tolerant persister cells in cancer. Vol. 203, Pharmacological Research. Academic Press; 2024.","DOI":"10.1016\/j.phrs.2024.107163"},{"issue":"5","key":"1966_CR21","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/cancers13051118","volume":"13","author":"G De Conti","year":"2021","unstructured":"De Conti G, Dias MH, Bernards R. Fighting drug resistance through the targeting of drug-tolerant persister cells. Cancers (Basel). 2021;13(5):1118.","journal-title":"Cancers (Basel)"},{"issue":"7679","key":"1966_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551(7679):247\u201350.","journal-title":"Nature"},{"issue":"10","key":"1966_CR23","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","volume":"24","author":"M Russo","year":"2024","unstructured":"Russo M, Chen M, Mariella E, Peng H, Rehman SK, Sancho E, et al. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nat Rev Cancer.  2024;24(10):694\u2013717.","journal-title":"Nat Rev Cancer"},{"key":"1966_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104483","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Tan Y, Huang C, Wei X. Redox signaling in drug-tolerant persister cells as an emerging therapeutic target. EBioMedicine. 2023. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104483.","journal-title":"EBioMedicine"},{"key":"1966_CR25","doi-asserted-by":"crossref","unstructured":"Mikubo M, Inoue Y, Liu G, Tsao MS. Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy. Vol. 16, Journal of Thoracic Oncology. Elsevier Inc.; 2021. p. 1798\u2013809.","DOI":"10.1016\/j.jtho.2021.07.017"},{"issue":"1","key":"1966_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69\u201380.","journal-title":"Cell"},{"issue":"7873","key":"1966_CR27","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","volume":"596","author":"Y Oren","year":"2021","unstructured":"Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, H\u00fctter JC, et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature. 2021;596(7873):576\u201382.","journal-title":"Nature"},{"key":"1966_CR28","unstructured":"Ramchandra M, Amnekar V. Phosphoacetylation of histones during cellular transformation in mammalian cells. PhD Thesis, Homi Bhabha National Institute, Mumbai, February 2021."},{"key":"1966_CR29","doi-asserted-by":"crossref","unstructured":"Natu A, Pedgaonkar A, Gupta S. Mitochondrial dysfunction and chromatin changes with autophagy-mediated survival in doxorubicin resistant cancer cell lines. Biochem Biophys Res Commun. 2023;648.","DOI":"10.1016\/j.bbrc.2023.01.081"},{"key":"1966_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.mrfmmm.2015.01.017","volume":"773","author":"AK Sharma","year":"2015","unstructured":"Sharma AK, Bhattacharya S, Khan SA, Khade B, Gupta S. Dynamic alteration in H3 serine 10 phosphorylation is G1-phase specific during ionization radiation induced DNA damage response in human cells. Mutat Res. 2015;773:83\u201391.","journal-title":"Mutat Res"},{"issue":"2","key":"1966_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3109\/07388551.2015.1128876","volume":"37","author":"A Adan","year":"2017","unstructured":"Adan A, Alizada G, Kiraz Y, Baran Y, Nalbant A. Flow cytometry: basic principles and applications. Crit Rev Biotechnol. 2017;37(2):163\u201376.","journal-title":"Crit Rev Biotechnol"},{"key":"1966_CR32","first-page":"7","volume":"19","author":"M Ramirez","year":"2016","unstructured":"Ramirez M, Rajaram S, Steininger RJ, Osipchuk D, Roth MA, Morinishi LS, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun. 2016;19:7.","journal-title":"Nat Commun"},{"key":"1966_CR33","doi-asserted-by":"crossref","unstructured":"Mirzayans R, Murray D. Intratumor heterogeneity and therapy resistance: contributions of dormancy, apoptosis reversal (Anastasis) and cell fusion to disease recurrence. Int J Mol Sci. 2020;.","DOI":"10.3390\/ijms21041308"},{"issue":"2","key":"1966_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2017.07.002","volume":"32","author":"GD Guler","year":"2017","unstructured":"Guler GD, Tindell CA, Pitti R, Wilson C, Nichols K, KaiWai Cheung T, et al. Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure. Cancer Cell. 2017;32(2):221-237.e13.","journal-title":"Cancer Cell"},{"issue":"7679","key":"1966_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551(7679):247\u201350.","journal-title":"Nature"},{"issue":"7524","key":"1966_CR36","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/nature13611","volume":"514","author":"A Viale","year":"2014","unstructured":"Viale A, Pettazzoni P, Lyssiotis CA, Ying H, S\u00e1nchez N, Marchesini M, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514(7524):628\u201332.","journal-title":"Nature"},{"issue":"3","key":"1966_CR37","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1158\/0008-5472.CAN-22-2370","volume":"83","author":"L Yun","year":"2023","unstructured":"Yun L, Chen H, Xie X, Yang B, XWang I, Zhang J, et al. PINK1-mediated mitophagy promotes oxidative phosphorylation and redox homeostasis to induce drug-tolerant persister cancer cells. Cancer Res. 2023;83(3):398\u2013413.","journal-title":"Cancer Res"},{"key":"1966_CR38","doi-asserted-by":"crossref","unstructured":"Shen S, Faouzi S, Bastide A, Martineau S, Malka-Mahieu H, Fu Y, et al. An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. Nat Commun. 2019 Dec 1;10(1).","DOI":"10.1038\/s41467-019-13360-6"},{"key":"1966_CR39","doi-asserted-by":"crossref","unstructured":"Baratchian M, Tiwari R, Khalighi S, Chakravarthy A, Yuan W, Berk M, et al. H3K9 methylation drives resistance to androgen receptor\u2013antagonist therapy in prostate cancer. Proc Natl Acad Sci U S A. 2022;119(21).","DOI":"10.1073\/pnas.2114324119"},{"key":"1966_CR40","doi-asserted-by":"crossref","unstructured":"Manj\u00f3n AG, Manzo SG, Prekovic S, Potgeter L, van Schaik T, Liu NQ, et al. Perturbations in 3D genome organization can promote acquired drug resistance. Cell Rep. 2023;42(10).","DOI":"10.1016\/j.celrep.2023.113124"},{"key":"1966_CR41","doi-asserted-by":"crossref","unstructured":"Zhao H, Lin LF, Hahn J, Xie J, Holman HF, Yuan C. Single-cell image-based analysis reveals chromatin changes during the acquisition of tamoxifen drug resistance. Life (Basel). 2022;12(3).","DOI":"10.3390\/life12030438"},{"key":"1966_CR42","doi-asserted-by":"crossref","unstructured":"Menon DR, Hammerlindl H, Torrano J, Schaider H, Fujita M. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer. Vol. 10, Theranostics. Ivyspring International Publisher; 2020. p. 6261\u201377.","DOI":"10.7150\/thno.42523"},{"key":"1966_CR43","doi-asserted-by":"crossref","unstructured":"Marsolier J, Prompsy P, Durand A, Lyne AM, Landragin C, Trouchet A, et al. H3K27me3 conditions chemotolerance in triple-negative breast cancer. Nat Genet. 2022;54(4).","DOI":"10.1038\/s41588-022-01047-6"},{"issue":"4","key":"1966_CR44","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1021\/acs.jproteome.9b00773","volume":"19","author":"V Pham","year":"2020","unstructured":"Pham V, Pitti R, Tindell CA, Cheung TK, Masselot A, Stephan JP, et al. Proteomic analyses identify a novel role for EZH2 in the initiation of cancer cell drug tolerance. J Proteome Res. 2020;19(4):1533\u201347.","journal-title":"J Proteome Res"},{"issue":"7","key":"1966_CR45","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1158\/0008-5472.CAN-15-2125","volume":"76","author":"KB Chiappinelli","year":"2016","unstructured":"Chiappinelli KB, Zahnow CA, Ahuja N, Bylin SB. Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 2016;76(7):1683\u20139.","journal-title":"Cancer Res"},{"key":"1966_CR46","doi-asserted-by":"crossref","unstructured":"Lunke S, Maxwell S, Khurana I, K.N H, Okabe J, Al-Hasani K, et al. 2021. Epigenetic evidence of an Ac\/Dc axis by VPA and SAHA. Clin Epigenetics. 13(1).","DOI":"10.1186\/s13148-021-01050-4"},{"key":"1966_CR47","doi-asserted-by":"crossref","unstructured":"Truong TG, Munster P. Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data. Clin Investig (Lond). 2013;3(6).","DOI":"10.4155\/cli.13.35"},{"issue":"6","key":"1966_CR48","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3748\/wjg.v26.i6.598","volume":"26","author":"RV Amnekar","year":"2020","unstructured":"Amnekar RV, Khan SA, Rashi M, Khade B, Thorat R, Gera P, et al. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer. World J Gastroenterol. 2020;26(6):598\u2013613.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1966_CR49","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13148-019-0800-4","volume":"12","author":"A Sharda","year":"2020","unstructured":"Sharda A, Rashid M, Shah SG, Sharma AK, Singh SR, Gera P, et al. Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells. Clin Epigenetics. 2020;12(1):4.","journal-title":"Clin Epigenetics"},{"key":"1966_CR50","doi-asserted-by":"crossref","unstructured":"Natu A, Verma T, Khade B, Thorat R, Gera P, Dhara S, et al. Histone acetylation: a key determinant of acquired cisplatin resistance in cancer. Clin Epigenetics. 2024 Dec 1;16(1).","DOI":"10.1186\/s13148-023-01615-5"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01966-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-025-01966-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-025-01966-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:22:09Z","timestamp":1759918929000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-025-01966-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1966"],"URL":"https:\/\/doi.org\/10.1186\/s13148-025-01966-1","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted after approval from the Institutional Animal Ethical Committee (Project No. 45\/2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}],"article-number":"168"}}